Clinical Trial Update: A Pharmacokinetic Study of VCT220 in Particicants With Hepatic Injury and Normal Hepatic Function [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study of VCT220 in participants with hepatic injury and normal hepatic function (completed), sponsored by Vincentage Pharma Co., Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Injury
• Obesity

Drugs mentioned

• VCT220

Snippet

Sponsor: Vincentage Pharma Co., Ltd | Conditions: Obesity, Overweight | Phase 1 | Status: COMPLETED